Safety Study of FP-1039 To Treat Cancer

Phase 1

Completed

• Conditions: Advanced Cancer
• Interventions: Drug: FP-1039

• Registration Number: NCT00687505
• Lead Sponsor: Five Prime Therapeutics, Inc.

Brief Summary

The primary purpose of this study is to evaluate the safety and tolerability of FP-1039, a new biologic treatment for cancer.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2008-05-27
• Study First Submitted QC: 2008-05-27
• Study First Posted: 2008-05-30
• Study Start: 2008-07
• Primary Completion: 2011-05
• Study Completion: 2011-06
• Status Verified: 2021-12
• Last Update Submitted: 2021-12-09
• Last Update Posted: 2021-12-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 39

Inclusion Criteria

• Subjects with metastatic or locally advanced unresectable solid tumors for which standard curative or supportive measures do not exist or are no longer effective
• Male or female 18 years of age or older

Exclusion Criteria

• Presence or history of melanoma
• Primary brain tumor
• Presence or history of glaucoma

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	FP-1039	Single ascending doses

Primary Outcome Measures

Name	Time	Method
Safety and tolerability	4 weeks

Trial Locations

Locations (2)

Karmanos Cancer Institute; 🇺🇸 Detroit, Michigan, United States

START (South Texas Accelerated Research Therapeutics); 🇺🇸 San Antonio, Texas, United States